Actively Recruiting
Optimizing Tafenoquine Dosing for Radical Cure of Plasmodium Vivax Malaria in Southeast Asia with Comparative Primaquine Arm in Indonesia
Led by University of Oxford · Updated on 2026-10-09
820
Participants Needed
6
Research Sites
18 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the optimal dose of tafenoquine for treating Plasmodium vivax malaria in Southeast Asia. This study compares the current recommended 300 mg dose of tafenoquine, which is less effective in this region, to a 50% higher dose. The trial also includes a comparison to high-dose primaquine in Indonesia, where primaquine is the standard care. The goal is to improve radical cure rates by reducing malaria recurrence. Participants will be randomly assigned to receive either the standard tafenoquine dose or a higher dose, both given as a single dose adjusted by weight bands. In Indonesia, a third group will receive high-dose primaquine daily for seven days. All participants will receive a schizonticidal agent such as chloroquine or artemether-lumefantrine alongside tafenoquine or primaquine. Drug administration will be directly observed to ensure adherence, and the treatments are given according to the national malaria guidelines. Participants will be followed daily until malaria parasites clear and then at several scheduled visits up to 4 months. These visits include blood tests, physical exams, and monitoring of adverse events and drug levels. If malaria recurs, treatment and follow-up restart as a new episode. The study measures include recurrence of infection by microscopy and molecular methods, adverse events, and drug levels over time. Data confidentiality and quality control procedures are in place, with a total participation duration of 4 months per episode.
CONDITIONS
Brief Title
Southeast Asia Dose Optimization of Tafenoquine
Research Team
C
Cindy Chu, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here